Aktuellt
SENASTE
We make limited revisions to our estimates after Q4 and set a valuation range of SEK 61-81 per share (largely unchanged). The main news during Q4 was the first step in Bactiguard’s reshaped strategy, with the BD agreement being expanded with sales exclusivity in more markets. More deals, including the central venous catheter and endotracheal tube areas and in other segments, are needed for Bactiguard to reach its targets, but this is a good first step.
LÄS MER
